Please login to the form below

Not currently logged in
Email:
Password:

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

J&J

Johnson & Johnson has an FDA green light to start a new trial of the CAR-T therapy for multiple myeloma it licensed from China’s Legend Biotech for a whopping $350m upfront last December.

Legend’s anti-BCMA CAR-T - called LCAR-B38M and now rebadged as JNJ-68284528 by J&J’s Janssen division - hit the headlines at last year’s American Society of Clinical Oncology (ASCO) meeting after Legend presented stellar data from an early-stage trial that showed a 100% objective response rate in treatment-resistant, relapsed myeloma patients.

The new phase I/II trial, due to get underway in the second half of the year, will also enrol patients with relapsed or refractory multiple myeloma and will start with a phase 1b trial to determine a suitable dose to take forward to the phase II portion, which will gauge efficacy using overall response rate as a primary endpoint.

J&J is going up against some well-positioned competitors in the anti-BCMA CAR-T category, notably Celgene and Bluebird Bio with bb2121, Celgene and Juno with and Kite Pharma/Gilead Sciences’ KITE-585, both of which are on the agenda of this year’s ASCO which gets underway on Friday.

There are other candidates in the pipeline too, including TeneoBio’s TNB-383B, a therapy developed by China’s Pregene Biotech, as well as at least three others in investigator-sponsored trials in China and the US.

In the US alone, there are more than 30,000 new cases of myeloma every year, causing around 12,000 deaths a year and - despite an increasing number of treatment options - the disease remains incurable and CAR-T is viewed as a potentially important new treatment option.

The start of the trial is another signpost on J&J’s road to developing a position in cancer immunotherapy as it tries to catch the leaders in the category such as Bristol-Myers Squibb, Merck & Co and Roche.

Earlier this month it bought oncolytic virus player Benevir Biopharm for $140m upfront and up to $900m in milestones, and also has a collaboration with Aduro for cancer vaccine ADU-214 as well as some in-house projects such as PD-1 checkpoint inhibitor JNJ-63723283, but it is still a minnow among the big fish in immuno-oncology.

Meanwhile, hopes that its anti-CD38 Darzalex (daratumumab) could find a role alongside checkpoint inhibitors in blood cancers and solid tumours took a knock earlier this week after safety issues led to two the termination of two trials of the drug in combination with Roche’s Tecentriq (atezolizumab) and JNJ-63723283.

Article by
Phil Taylor

31st May 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics